drugset / Trial / NCT00420186
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical research is to assess the safety and tolerability of BMS-690514 when given in combination with paclitaxel and carboplatin. Paclitaxel and carboplatin will be administered on a standard regimen every 3 weeks at standard doses. BMS-690514 will be given in the interval at escalating doses until the maximum tolerated dose (MTD) is identified. An additional cohort of subjects will be treated with BMS-690514 at the MTD in combination with Paclitaxel and carboplatin
Timeline
- Start
- 2007-10
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-690514 | Small molecule | 100 mg | Oral |
| Subject | BMS-690514 | Small molecule | 300 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |
Indications
No indication recorded.